E/M Coding Alert - 2007 Issue 31
COMPLIANCE: OIG Wants To Squeeze Your Drug Payments Further
Subscribe or sign in to view the full article.
Article Overview
This compliance-focused article covers an OIG report examining Medicare Part B drug payment levels against wholesaler pricing and the resulting policy concerns raised for CMS. It is relevant to coders, billing staff, compliance teams, and reimbursement professionals who track Medicare drug payment methodology, payment integrity reviews, and federal oversight activity. The article also notes specific drug code examples cited in the discussion and the broader context of potential payment changes.
Why This Topic Matters
The piece highlights how federal oversight of Part B drug reimbursement can affect payment policy and future Medicare payment calculations. It matters to organizations that bill or track Medicare drug claims because OIG findings may influence agency reviews, compliance attention, and reimbursement strategy.
What You Will Learn
- How OIG reviews Medicare Part B drug payment levels
- Why ASP-based payment methodology is being scrutinized
- How OIG and CMS differ on what information is needed for payment analysis
- What kinds of policy and reimbursement issues can arise from drug payment reviews
Who Should Read This
- Medical coders
- Billing staff
- Compliance officers
- Revenue cycle professionals
- Reimbursement analysts
- Practice administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com